Moderna, Inc. Furnishes Update on FDA Refusal-to-File for mRNA-1010
Summary
Moderna, Inc. announced on February 10, 2026, that the FDA's Center for Biologics Evaluation and Research (CBER) issued a Refusal-to-File (RTF) letter for its investigational seasonal influenza vaccine, mRNA-1010 (via Ex. 99.1). This means the FDA will not initiate a review of the Biologics License Application (BLA). The RTF cited the choice of a licensed standard-dose seasonal influenza vaccine comparator as the sole reason. Moderna has requested a Type A meeting to understand the path forward.
Why It Matters
The FDA's Refusal-to-File for mRNA-1010 delays the potential market entry of Moderna's investigational seasonal influenza vaccine in the U.S. However, Moderna "does not expect any impact on its 2026 financial guidance" (via Ex. 99.1). This indicates a regulatory setback for a pipeline product without immediate financial repercussions.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On February 10, 2026, Moderna, Inc. (the "Company") issued a press release regarding the receipt of a Refusal-to-File letter from the U.”
— From Item 7.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Wednesday, February 11, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral